COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Dummer, Reinhard; Flaherty, Keith T.; Robert, Caroline; Arance, Ana; de Groot, Jan Willem B.; Garbe, Claus; Gogas, Helen J.; Gutzmer, Ralf; Krajsova, Ivana; Liszkay, Gabriella; Loquai, Carmen; Mandala, Mario; Schadendorf, Dirk; Yamazaki, Naoya; di Pietro, Alessandra; Cantey-Kiser, Jean; Edwards, Michelle; Ascierto, Paolo A.

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Autor(en):

Dummer, Reinhard; Flaherty, Keith T.; Robert, Caroline; Arance, Ana; de Groot, Jan Willem B.; Garbe, Claus; Gogas, Helen J.; Gutzmer, Ralf; Krajsova, Ivana; Liszkay, Gabriella; Loquai, Carmen; Mandala, Mario; Schadendorf, Dirk; Yamazaki, Naoya; di Pietro, Alessandra; Cantey-Kiser, Jean; Edwards, Michelle; Ascierto, Paolo A.

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

Journal of Clinical Oncology (2022), Bd. 40, H. 36, S. 4178

Verlagsangabe:

Philadelphia : Lippincott Williams & Wilkins

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1200/JCO.21.02659

ISSN:

0732-183X